Spyre Therapeutics Inc. (SYRE)
Spyre Therapeutics Statistics
Share Statistics
Spyre Therapeutics has 60.26M shares outstanding. The number of shares has increased by 18.66% in one year.
| Shares Outstanding | 60.26M |
| Shares Change (YoY) | 18.66% |
| Shares Change (QoQ) | 2.64% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 51.14M |
| Failed to Deliver (FTD) Shares | 1.87K |
| FTD / Avg. Volume | 0.28% |
Short Selling Information
The latest short interest is 10M, so 17.04% of the outstanding shares have been sold short.
| Short Interest | 10M |
| Short % of Shares Out | 17.04% |
| Short % of Float | 20.04% |
| Short Ratio (days to cover) | 18.83 |
Valuation Ratios
The PE ratio is -41.9 and the forward PE ratio is -5.21. Spyre Therapeutics's PEG ratio is 0.42.
| PE Ratio | -41.9 |
| Forward PE | -5.21 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 16.83 |
| P/FCF Ratio | -55.37 |
| PEG Ratio | 0.42 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Spyre Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.26, with a Debt / Equity ratio of 0.
| Current Ratio | 11.26 |
| Quick Ratio | 11.26 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.2M |
| Employee Count | 65 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -51K |
| Effective Tax Rate | 0.02% |
Stock Price Statistics
The stock price has increased by -66.77% in the last 52 weeks. The beta is 3.06, so Spyre Therapeutics's price volatility has been higher than the market average.
| Beta | 3.06 |
| 52-Week Price Change | -66.77% |
| 50-Day Moving Average | 19.64 |
| 200-Day Moving Average | 25.72 |
| Relative Strength Index (RSI) | 24.6 |
| Average Volume (20 Days) | 661.98K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -208.57M |
| Net Income | -208.02M |
| EBITDA | -208.57M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.56 |
Balance Sheet
The company has 89.42M in cash and 0 in debt, giving a net cash position of 89.42M.
| Cash & Cash Equivalents | 89.42M |
| Total Debt | 0 |
| Net Cash | 89.42M |
| Retained Earnings | -972.43M |
| Total Assets | 608.48M |
| Working Capital | 554.41M |
Cash Flow
In the last 12 months, operating cash flow was -157.41M and capital expenditures 0, giving a free cash flow of -157.41M.
| Operating Cash Flow | -157.41M |
| Capital Expenditures | 0 |
| Free Cash Flow | -157.41M |
| FCF Per Share | -0.42 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SYRE is $45, which is 264.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $45 |
| Price Target Difference | 264.7% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Sep 8, 2023. It was a backward split with a ratio of 1:25.
| Last Split Date | Sep 8, 2023 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | 3.9 |
| Piotroski F-Score | 3 |